Dr. Matthew M. Lander, M.D.
Heart Failure & Transplant Cardiology (Advanced Heart Failure and Transplant Cardiology Physician)
- Medicare participating
At a glance
- Medical school
- Drexel University College of Medicine (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 165
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: Drexel University College of Medicine
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Advanced Heart Failure and Transplant Cardiology Physician primary
PA license MD447953 -
Cardiovascular Disease Physician
PA license MD447953
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: Heart Failure & Transplant Cardiology per capita by county →
Where they work
Hospitals
- Allegheny General Hospital Pittsburgh, PA
- West Penn Hospital Pittsburgh, PA
- Ahn Wexford Hospital Wexford, PA
- Heritage Valley Beaver Beaver, PA
- Canonsburg General Hospital Canonsburg, PA
Medical groups
- Allegheny Clinic (2,389 clinicians)
- Las Geriatric Care Services, Inc. (35 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 165
- Services billed
- 528
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 89 | 32 |
| Established patient office or other outpatient visit, 30-39 minutes | 79 | 65 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 70 | 23 |
| Established patient office or other outpatient visit, 40-54 minutes | 64 | 53 |
| Critical care, first 30-74 minutes | 57 | 23 |
| Remote monitoring of pulmonary artery pressure sensor, up to 30 days | 52 | 17 |
| Hospital discharge day management, more than 30 minutes | 20 | 18 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 16 | 15 |
| New patient office or other outpatient visit, 60-74 minutes | 15 | 15 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Spironolactone Other prescribers in Pittsburgh, PA | 557 |
| Entresto (sacubitril/valsartan) Other prescribers in Pittsburgh, PA | 402 |
| Metoprolol Succinate Other prescribers in Pittsburgh, PA | 331 |
| Jardiance (empagliflozin) Other prescribers in Pittsburgh, PA | 272 |
| Carvedilol Other prescribers in Pittsburgh, PA | 205 |
| Furosemide Other prescribers in Pittsburgh, PA | 204 |
| Bumetanide Other prescribers in Pittsburgh, PA | 152 |
| Eliquis (apixaban) Other prescribers in Pittsburgh, PA | 133 |
| Atorvastatin Calcium Other prescribers in Pittsburgh, PA | 108 |
| Lisinopril Other prescribers in Pittsburgh, PA | 86 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 16 payments worth $1,673 in total to this clinician.
| Abiomed | $1,268 |
|---|---|
| Endotronix, Inc. | $235 |
| Abbott Laboratories | $141 |
| United Therapeutics Corporation | $29.14 |
| Food and Beverage | $1,038 |
|---|---|
| Travel and Lodging | $636 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Abiomed Mar 10, 2025 | Travel and Lodging travel to Boston, MA · in-kind | $252 |
| Abiomed Feb 10, 2025 | Travel and Lodging travel to BOSTON, MA | $220 |
| Abiomed Feb 10, 2025 | Travel and Lodging travel to BOSTON, MA · in-kind | $161 |
| Abiomed Mar 10, 2025 | Travel and Lodging travel to Boston, MA · in-kind | $2.72 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $109,985 in research payments for these studies, mostly to the institutions running them.
- Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy
Impulse Dynamics (USA) Inc. · Active, not recruiting · NCT03970343 - NCT06526195--Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
Abbott Laboratories - REDEFINE-HF Study #22438
Bayer HealthCare Pharmaceuticals Inc. - Assessment of CCM in HF With Higher Ejection Fraction
Impulse Dynamics (USA) Inc. · Recruiting · NCT05064709
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.